Jeffrey C Goh
机构: University of Queensland, Royal Brisbane & Women's Hospital
每年引用次数
引用次数
引用: 7,602
H-指数: 29
I10-指数 : 56
出版物: 178
Compatibility of the Omnican (R) Pen Needles with Insulin Pens, Humapen (R) and Novopen (R)
Kam Cheong Wong , Ying Wei Lum , Ammu K. Radhakrishnan , Jeffrey Goh
Journal of the ASEAN Federation of Endocrine Societies 20 36 -39
2002
Testicular Cancer Surveillance-How Close are We to Following ANZUP Guidelines?
Jeffrey Goh , Laura Tam , Aneta Suder , Jessica Cook
Asia-pacific Journal of Clinical Oncology 15 53 -53
2019
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer (mCRPC): A retrospective multicentre analysis
David Pook , Francis Parnis , Andrew Weickhardt , Shirley Wong
Asia-pacific Journal of Clinical Oncology 15 117 -117
2019
Real-World Use of First-Generation Anti-androgens (FGAs): Their Influence on Patient Outcomes and Subsequent Therapies in Metastatic Castration-Resistant Prostate Cancer (mCPRC)
David Pook , Francis Parnis , Andrew Weickhardt , Shirley Wong
Asia-pacific Journal of Clinical Oncology 15
2019
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Michelle Harrison , Michael L. Friedlander , Katrin M. Sjoquist , Linda Mileshkin
Gynecologic Oncology 161 ( 2) 374 -381
2021
TheraP: A randomised phase 2 trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel - initial results (ANZUP protocol 1603).
Margaret McJannett , Michael Hofman , Scott Williams , Ian D Davis
Asia-pacific Journal of Clinical Oncology 16
2020
177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
Andrew Redfern , Michael Hofman , Andrew Weickhardt , William Macdonald
The Journal of Nuclear Medicine 62 1703 -1703
2021
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Linda Mileshkin , Richard Edmondson , Rachel L O'Connell , Katrin M Sjoquist
Gynecologic Oncology 154 ( 1) 29 -37
10
2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Monica Tang , Rachel L. O'Connell , Frederic Amant , Philip Beale
Gynecologic Oncology 154 ( 3) 531 -538
21
2019
PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
Peey-Sei Kok , Philip Beale , Rachel L. O'Connell , Peter Grant
Journal of Gynecologic Oncology 30 ( 5)
6
2019
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Andreas Obermair , Linda Mileshkin , Katharina Bolz , Srinivas Kondalsamy-Chennakesavan
Gynecologic Oncology 120 ( 2) 179 -184
13
2011
Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma
Nicola J. Lawrence , Andrew Martin , Ian D. Davis , Simon Troon
Kidney Cancer 4 ( 4) 185 -195
2020
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S. Antonarakis , Josep M. Piulats , Marine Gross-Goupil , Jeffrey Goh
Journal of Clinical Oncology 38 ( 5) 395 -405
385
2020
Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options
Andrew Schmidt , Arun Azad , Jeffrey Goh , Carole Harris
Asia-pacific Journal of Clinical Oncology 15 3 -10
2
2019
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease
Andrew Schmidt , Angelyn Anton , Julia Shapiro , Shirley Wong
Asia-pacific Journal of Clinical Oncology 17 ( 1) 36 -42
2
2021
Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Satyamurthy Anuradha , Peter J. Donovan , Penelope M. Webb , Alison H. Brand
Acta Oncologica 55 ( 2) 226 -233
10
2016
Abstract CT167: A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
Jeffrey Goh , Ben Gao , Ben Markman , Hui Gan
Cancer Research 79 ( 13)
2019
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Michael Friedlander , Susana Banerjee , Linda Mileshkin , Clare Scott
Asia-pacific Journal of Clinical Oncology 12 ( 4) 323 -331
16
2016
Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib
Michael Friedlander , Catherine Shannon , Jeffrey Goh , Clare Scott
Asia-pacific Journal of Clinical Oncology 14 ( 6) 459 -464
4
2018
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures
Kenneth Pittman , Yoland C Antill , Amanda Goldrick , Jeffrey Goh
Asia-pacific Journal of Clinical Oncology 13 ( 4) 266 -276
19
2017